Replies to post #689873 on NorthWest Biotherapeutics Inc (NWBO)

[theorysuit]

you can't argue with the pumpers, they are so blinded.

[Doc logic]

iclight,

That would be like someone asking you why you are not an NWBO basher. L does work so no need to ask why it doesn’t anymore than anyone needs to ask why you are not an NWBO basher. You are.
Now if you want to know about how L can work better then you might want to read up on Poly ICLC, CSF-R1, checkpoint inhibitor pembro used in combination with L and RevImmune’s IL 7 product for boosting T-cell performance; ). Best wishes.

[dstock07734]

IC,

The Nature paper is just the beginning. The case study paper was accepted for publication. The following paper could be published anytime too which could be more significant since never before NCI top-notch scientists did such type of analysis on samples from a phase 3 trial totally run by a company. The implications are significant. The paper on the combo trial should be published this year. Likewise a paper from the highly secrete colorectal trial. Here are the words from the JAMA paper. Seems to me there could be another paper.

Although the primary end points of this study focused on OS, exploratory analyses of immunogenicity and biomarkers of immune activation and sensitization that may correlate with therapeutic benefit are planned. We have previously shown that CD8 + and CD4 + T cells can traffic into glioblastomas following DC vaccination, which correlates with survival,37,38 and we plan to confirm these prior findings with this larger phase 3 data set.

Glioblastoma Molecular Characteristics and Immune Microenvironment Associated with Survival Outcomes in Patients Treated with Dendritic Cell Vaccination
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249282